EMA Confirms Recommendation Of Synchron Suspensions
But Finds Alternative Data To Support Marketing Authorizations For Eight Medicines
Following a review of an earlier decision, the European Medicines Agency has confirmed its recommendation to suspend marketing authorizations for dozens of medicines with bioequivalence studies conducted by Synchron Research Services. However, eight products have been spared after alternative supporting data was identified.
You may also be interested in...
UAE’s Bioventure Is Looking For Partners To Expand
Having recently added to its biosimilars alliance with Alvotech, Dubai-based Bioventure says it is looking to expand its international reach through further partnerships.
Medicines For Europe Highlights Industry Agenda
Ahead of its annual meeting in Malta in mid-June, European off-patent industry association Medicines for Europe has set out the hot topics for generics and biosimilars stakeholders that delegates will be looking to discuss.
Who’s Hired? New Mithra CEO Mulls Selling Generics Business
Mithra’s new CEO has immediately signaled a potential sale for the firm’s generics business as it looks to focus on branded assets in women’s health. Meanwhile, Sawai has reorganized its management team, the longtime chair of Viatris is moving on to another role, and a former AAM vice-president has joined Sandoz.